References
- Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–397. doi:https://doi.org/10.1097/AOG.0b013e3182605bf1.
- Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of endometrial carcinoma: Etiologic importance of hormonal and metabolic influences. Adv Exp Med Biol. 2017;943:3–46. doi:https://doi.org/10.1007/978-3-319-43139-0_1.
- Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, Part 1: National cancer statistics. J Natl Cancer Inst. 2021;113(12):1648–1669. doi:https://doi.org/10.1093/jnci/djab131.
- Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019;58(3):342–352. doi:https://doi.org/10.1080/0284186X.2018.1540886.
- Terzic M, Aimagambetova G, Kunz J, et al. Molecular basis of endometriosis and endometrial cancer: Current knowledge and future perspectives. IJMS. 2021;22(17):9274. doi:https://doi.org/10.3390/ijms22179274.
- Nowak-Markwitz E, Michalak M, Spaczyński M. Prediction value of serum Ca 125 level in benefit secondary cytoreduction in advanced ovarian cancer patients. Współcz Onkol. 2003;7:662–667.
- Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008;31(2):207–214. doi:https://doi.org/10.1097/CJI.0b013e31816060ce.
- Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997;90(3):441–447. doi:https://doi.org/10.1016/S0029-7844(97)00286-X.
- Giampaolino P, Foreste V, Della Corte L, Di Filippo C, Iorio G, Bifulco G. Role of biomarkers for early detection of ovarian cancer recurrence. Gland Surg. 2020;9(4):1102–1111. doi:https://doi.org/10.21037/gs-20-544.
- Patsner B, Orr JW, Jr, Mann WJ.Jr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol. 1990;162(2):427–429. doi:https://doi.org/10.1016/0002-9378(90)90400-2.
- Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol. 2000;182(6):1328–1334. doi:https://doi.org/10.1067/mob.2000.106251.
- Szubert M, Suzin J, Wierzbowski T, Kowalczyk-Amico K. CA-125 concentration in serum and peritoneal fluid in patients with endometriosis - preliminary results. AOMS. 2012;3(3):504–508. doi:https://doi.org/10.5114/aoms.2012.29407.
- Deen S. FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol. 2009;28(5):477–478. doi:https://doi.org/10.1097/PGP.0b013e3181a71bef.
- Sroczynski G, Gogollari A, Conrads-Frank A, et al. Cost-effectiveness of early detection and prevention strategies for endometrial cancer-A systematic review. Cancers (Basel). 2020;12(7):1874. doi:https://doi.org/10.3390/cancers12071874.
- Giampaolino P, Della Corte L, Foreste V, et al. Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer. Minerva Med. 2019;110(4):279–291. doi:https://doi.org/10.23736/S0026-4806.19.06086-5.
- Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002;86(1):28–33. doi:https://doi.org/10.1006/gyno.2002.6664.
- Sebastianelli A, Renaud MC, Grégoire J, Roy M, Plante M. Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can. 2010;32(9):856–860. doi:https://doi.org/10.1016/S1701-2163(16)34657-6.
- Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC.Jr. Elevation of serum CA-125 in carcinoma of the fallopian tube, endometrium and endoservix. Am J Obstet Gynecol. 1984;148(8):1057–1058. doi:https://doi.org/10.1016/S0002-9378(84)90444-7.
- Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC.Jr. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol. 1990;163(4 Pt 1):1204–1209. doi:https://doi.org/10.1016/0002-9378(90)90692-Z.
- Lo SS, Cheng DK, Ng TY, Wong LC, Ngan HY. Prognostic significance of tumour markers in endometrial cancer. Tumour Biol. 1997;18(4):241–249. doi:https://doi.org/10.1159/000218037.
- Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer. 1998;82(9):1720–1725. doi:https://doi.org/10.1002/(sici)1097-0142(19980501)82:9 < 1720:aid-cncr19 > 3.0.co;2-6.
- Reijnen C, Visser NC, Kasius JC, et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019;30(5):e70. doi:https://doi.org/10.3802/jgo.2019.30.e70.
- Watanabe M, Aoki Y, Kase H, Fujita K, Tanaka K. Low risk endometrial cancer: a study of pelvic lymph node metastasis. Int J Gynecol Cancer. 2003;13(1):38–41. doi:https://doi.org/10.1046/j.1525-1438.2003.13037.x.
- Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85(12):1501–1505. doi:https://doi.org/10.1080/00016340601022777.
- Topalak O, Saygili U, Soyturk M, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol. 2002;85(1):108–113. doi:https://doi.org/10.1006/gyno.2001.6575.
- Hunter VJ, Weinberg JB, Haney AF, et al. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol. 1990;36(2):161–65. doi:https://doi.org/10.1016/0090-8258(90)90165.